nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2007-11-4-28-46nefr-948Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESОСОБЕННОСТИ ФУНКЦИИ ЭНДОТЕЛИЯ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК. ОБЗОР ЛИТЕРАТУРЫ И СОБСТВЕННЫЕ ДАННЫЕSPECIFIC FUNCTIONS OF THE ENDOTHELIUM IN CHRONIC KIDNEY DISEASE. LITERATURE REVIEW AND PERSONAL DATAПанинаИ. Ю.PaninaI. Yu.

кафедра пропедевтики внутренних болезней, 

Научно-исследовательский  институт нефрологии, кафедра патофизиологии

РумянцевА. Ш.RumyantsevA. Sh.

кафедра пропедевтики внутренних болезней, 

Научно-исследовательский  институт нефрологии, кафедра патофизиологии

МеншутинаМ. А.MenshutinaM. A.

кафедра пропедевтики внутренних болезней, 

Научно-исследовательский институт нефрологии, кафедра патофизиологии

АчкасоваВ. В.AchkasovaV. V.

кафедра пропедевтики внутренних болезней, 

Научно-исследовательский  институт нефрологии, кафедра патофизиологии

ДегтереваО. А.DegterevaO. A.

кафедра пропедевтики внутренних болезней,

Научно-исследовательский институт нефрологии, кафедра патофизиологии

ТугушеваФ. А.TugushevaF. A.

кафедра пропедевтики внутренних болезней, 

Научно-исследовательский институт нефрологии, кафедра патофизиологии

ЗубинИ. М.ZubinaI. M.

кафедра пропедевтики внутренних болезней, 

Научно-исследовательский институт нефрологии, кафедра патофизиологии

Санкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаRussian Federation2007100420071142846Copyright © Панина И.Ю., Румянцев А.Ш., Меншутина М.А., Ачкасова В.В., Дегтерева О.А., Тугушева Ф.А., Зубин И.М., 20072007Панина И.Ю., Румянцев А.Ш., Меншутина М.А., Ачкасова В.В., Дегтерева О.А., Тугушева Ф.А., Зубин И.М.Panina I.Y., Rumyantsev A.S., Menshutina M.A., Achkasova V.V., Degtereva O.A., Tugusheva F.A., Zubina I.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/948

.

.

хроническая болезнь почексердечно-сосудистые осложненияэндотелийэндотелиальная дисфункцияchronic kidney diseasecardio-vascular complicationsendotheliumendothelial dysfunctionReferencesDavies MJ, Thomas АС. Plaque fissuring – the cause of acute myocardial infarction, sudden ischemic death, and creshendo angina. Brit Heart Jourrn 1985; 53: 363-373Davies MJ, Thomas АС. Plaque fissuring – the cause of acute myocardial infarction, sudden ischemic death, and creshendo angina. Brit Heart Jourrn 1985; 53: 363-373Fuster V, Lewis A. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 1994; 90: 2126-2146Fuster V, Lewis A. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 1994; 90: 2126-2146Falk E, Shah PK, Faster V. Coronary plaque disruption. Circulation 1995; 92: 657-671Falk E, Shah PK, Faster V. Coronary plaque disruption. Circulation 1995; 92: 657-671Петрищев НН. Современные аспекты эндотелиопротекции в клинической практике. Ангиопротекция в практике терапевта: Материалы III Конгресса терапевтов Санкт-Петербурга и Северо-Западного Федерального округа России. СПб., 2004; 3-6Петрищев НН. Современные аспекты эндотелиопротекции в клинической практике. Ангиопротекция в практике терапевта: Материалы III Конгресса терапевтов Санкт-Петербурга и Северо-Западного Федерального округа России. СПб., 2004; 3-6Петрищев НН, Власов ТД. Физиология и патофизиология эндотелия. В: Петрищев НН, ред. Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция.Изд-во СПбГМУ, СПб., 2003; 4-38Петрищев НН, Власов ТД. Физиология и патофизиология эндотелия. В: Петрищев НН, ред. Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция.Изд-во СПбГМУ, СПб., 2003; 4-38Britten MB, Zeiher AM, Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245(4): 315-321Britten MB, Zeiher AM, Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245(4): 315-321Шишкин АН, Кирилюк ДВ. Дисфункция эндотелия у пациентов с прогрессирующими заболеваниями почек. Нефрология 2005; 9(2): 16-22Шишкин АН, Кирилюк ДВ. Дисфункция эндотелия у пациентов с прогрессирующими заболеваниями почек. Нефрология 2005; 9(2): 16-22Noguera A, Busquets X, Sauleda J et al. Expression of adhesion molecules and G proteins in circulating neut trophils in chronic pulmonary disease. Am J Crit Care Med 1998; 158(5): 1664-1668Noguera A, Busquets X, Sauleda J et al. Expression of adhesion molecules and G proteins in circulating neut trophils in chronic pulmonary disease. Am J Crit Care Med 1998; 158(5): 1664-1668Гомазков ОА. Пептиды в кардиологии. Биохимия. Физиология. Патология. Информация. Анализ. Материк Альфа, М., 2000; 143Гомазков ОА. Пептиды в кардиологии. Биохимия. Физиология. Патология. Информация. Анализ. Материк Альфа, М., 2000; 143Дедов ИИ, Шестакова МВ, Кочемасова ТВ и др. Дисфункция эндотелия в развитии сосудистых осложнений сахарного диабета. Рос физиол журн им И.М. Сеченова 2001; 87(8): 1073-1084Дедов ИИ, Шестакова МВ, Кочемасова ТВ и др. Дисфункция эндотелия в развитии сосудистых осложнений сахарного диабета. Рос физиол журн им И.М. Сеченова 2001; 87(8): 1073-1084Shirahase H, Fujiwara M, Usui H, Kurahashi K. A possible role of thromboxane A2 in endothelium in maintaining resting tone and producing contractile response to acetylcholine and arachidonic acid in canine cerebral artery. Blood Vessels 1987; 24: 117-119Shirahase H, Fujiwara M, Usui H, Kurahashi K. A possible role of thromboxane A2 in endothelium in maintaining resting tone and producing contractile response to acetylcholine and arachidonic acid in canine cerebral artery. Blood Vessels 1987; 24: 117-119Kato T, Iwama Y, Okumura K et al. Prostaglandin H2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension 1990; 15: 475-482Kato T, Iwama Y, Okumura K et al. Prostaglandin H2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension 1990; 15: 475-482Marie I, Beny JL. Endothelial dysfunction in murine model of systemic sclerosis. J Invest Dermatol 2002; 119(6): 1379-1385Marie I, Beny JL. Endothelial dysfunction in murine model of systemic sclerosis. J Invest Dermatol 2002; 119(6): 1379-1385Cannon RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 1998; 44: 1809-1819Cannon RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 1998; 44: 1809-1819Forstermann U, Biossel JP, Kleinert H. Expressional control of the constitutive isofiorms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998; 12: 773-790Forstermann U, Biossel JP, Kleinert H. Expressional control of the constitutive isofiorms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998; 12: 773-790Li H., Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000; 90: 244-254Li H., Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000; 90: 244-254Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res 1994; 31: 131-143Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res 1994; 31: 131-143Манухина ЕБ, Смирин БВ, Малышев ИЮ и др. Депонирование оксида азота в сердечно-сосудистой системе. Известия РАН. Серия биологическая 2002; 3Манухина ЕБ, Смирин БВ, Малышев ИЮ и др. Депонирование оксида азота в сердечно-сосудистой системе. Известия РАН. Серия биологическая 2002; 3Onda Т, Mashiko S, Hamano M et al. Enhancement of endothelium-dependent relaxation in the aorta from stroke-prone spontaneously hypertensive rats at developmental stages of hypertension. Clin Exp Pharm Physiol 1994; 2i: 857-863Onda Т, Mashiko S, Hamano M et al. Enhancement of endothelium-dependent relaxation in the aorta from stroke-prone spontaneously hypertensive rats at developmental stages of hypertension. Clin Exp Pharm Physiol 1994; 2i: 857-863Liischer TF. The endothelium in hypertension: bystander, target or mediator? J Hypertens1994; 12 [suppl 10]: S105-S116Liischer TF. The endothelium in hypertension: bystander, target or mediator? J Hypertens1994; 12 [suppl 10]: S105-S116Wever RMF, Liischer TF, Consentino F et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112Wever RMF, Liischer TF, Consentino F et al. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112Muijsers RBR, Folkets G, Henricks PAJ et al. Peroxynitrite: a two-faced metabolite of nitric oxide. Life Sci 1997; 60: 1833-1845Muijsers RBR, Folkets G, Henricks PAJ et al. Peroxynitrite: a two-faced metabolite of nitric oxide. Life Sci 1997; 60: 1833-1845Ванин АФ, Манухина ЕБ, Лапшин АВ, Меерсон ФЗ. Усиление синтеза оксида азота в стенке аорты при экспериментальном инфаркте миокарда. Бюл экспер биол 1993; 116(8): 142-144Ванин АФ, Манухина ЕБ, Лапшин АВ, Меерсон ФЗ. Усиление синтеза оксида азота в стенке аорты при экспериментальном инфаркте миокарда. Бюл экспер биол 1993; 116(8): 142-144Манухина ЕБ, Покидышев ДА, Маленюк ЕБ и др. Защитный эффект окиси азота при тепловом шоке. Известия РАН. Серия биологическая 1997; 1: 54-58Манухина ЕБ, Покидышев ДА, Маленюк ЕБ и др. Защитный эффект окиси азота при тепловом шоке. Известия РАН. Серия биологическая 1997; 1: 54-58Стокле Ж-К, Мюлле Б, Андрианцитохайна Р, Клещев А. Гиперпродукция оксида азота в патофизиологии кровеносных сосудов. Биохимия 1998; 63 (7): 976-983Стокле Ж-К, Мюлле Б, Андрианцитохайна Р, Клещев А. Гиперпродукция оксида азота в патофизиологии кровеносных сосудов. Биохимия 1998; 63 (7): 976-983Star RA. Nitric oxide: Southwestern Internal Medicine Conference. Am J Med Soc 1993; 306: 348-355Star RA. Nitric oxide: Southwestern Internal Medicine Conference. Am J Med Soc 1993; 306: 348-355Koch MA, Hasser EM, Schadt JC. Influence of nitric oxide on the hemodynamic response to hemorrhage in conscious rabbits. Am J Physiol 1995; 37: R171-R182Koch MA, Hasser EM, Schadt JC. Influence of nitric oxide on the hemodynamic response to hemorrhage in conscious rabbits. Am J Physiol 1995; 37: R171-R182Mitsuhara H, Takeuchi H, Saitoh J et al. An inhibitor of nitric oxide synthase, N(omega)-nitro-L-arginine-methyl ester, attenuates hypotension but does not improve cardiac depression in anaphylaxis in dogs. Shock 1995; 3: 447-453Mitsuhara H, Takeuchi H, Saitoh J et al. An inhibitor of nitric oxide synthase, N(omega)-nitro-L-arginine-methyl ester, attenuates hypotension but does not improve cardiac depression in anaphylaxis in dogs. Shock 1995; 3: 447-453Arnal J-F, Dinh-Xuan A-T, Pueyo M et al. Endothelium-derived nitric oxide and vascular physiology. Cell Mol Life 1999; 55: 1078-1087Arnal J-F, Dinh-Xuan A-T, Pueyo M et al. Endothelium-derived nitric oxide and vascular physiology. Cell Mol Life 1999; 55: 1078-1087Abrahamsson Т, Brandt U, Marklund SL et al. Vascular bound recombinant extracellular superoxide dismutase type С protect against the detrimental effects of superoxide radicals on endothelium-dependent arterial relaxation. Circulat Res 1992; 70: 264-271Abrahamsson Т, Brandt U, Marklund SL et al. Vascular bound recombinant extracellular superoxide dismutase type С protect against the detrimental effects of superoxide radicals on endothelium-dependent arterial relaxation. Circulat Res 1992; 70: 264-271Pagano PJ, Tornheim K, Cohen RA. Superoxide anion production by the rabbit thoracic aorta: Effect of endothelium-derived nitric oxide. Am J Physiol 1993; 265: H707-H712Pagano PJ, Tornheim K, Cohen RA. Superoxide anion production by the rabbit thoracic aorta: Effect of endothelium-derived nitric oxide. Am J Physiol 1993; 265: H707-H712Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Progr Cardio-Vasc Dis I995; 38: 105-128Cohen RA. The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Progr Cardio-Vasc Dis I995; 38: 105-128Feliciano L, Henning RJ. Coronary artery blood flow: physiologic and pathophysiologic regulation. Clin Cardiol 1999; 22: 775-786Feliciano L, Henning RJ. Coronary artery blood flow: physiologic and pathophysiologic regulation. Clin Cardiol 1999; 22: 775-786Galle J, Bauersachs J, Bassenge E, Busse R. Arterial size determines the enhancement of contractile responses after suppression of endothelium-derived relaxing factor formation. Pflugers Arch 1993; 422: 564-569Galle J, Bauersachs J, Bassenge E, Busse R. Arterial size determines the enhancement of contractile responses after suppression of endothelium-derived relaxing factor formation. Pflugers Arch 1993; 422: 564-569Lozano G, Pagliaro P, Gatullo D, Marsh NA. Control of coronary blood flow by endothelial release of nitric oxide. Clin Exp Pharmacol Physiol 1994; 21: 783-789Lozano G, Pagliaro P, Gatullo D, Marsh NA. Control of coronary blood flow by endothelial release of nitric oxide. Clin Exp Pharmacol Physiol 1994; 21: 783-789Levin ER. Endothelins. N Engl J Med 1995; 323: 356-363Levin ER. Endothelins. N Engl J Med 1995; 323: 356-363Schwarz P, Diem R, Dun NJ, Forstermann U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart synpathetic nerves. Circulat Res 1995; 77: 841-848Schwarz P, Diem R, Dun NJ, Forstermann U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart synpathetic nerves. Circulat Res 1995; 77: 841-848Hare J, Colluci WS. Role of nitric oxide in the regulation of myocardial function. Progr Cardiovasc Res 1995; 28: 155-166Hare J, Colluci WS. Role of nitric oxide in the regulation of myocardial function. Progr Cardiovasc Res 1995; 28: 155-166Lewis MJ, Shah AM. Endothelial modulation of myocardial contraction. Endothelium 1994; 1: 237-243Lewis MJ, Shah AM. Endothelial modulation of myocardial contraction. Endothelium 1994; 1: 237-243Welch G, Loscalzo J. Nitric oxide and cardiovascular system. J Cardiovasc Surg1994; 9: 361-371Welch G, Loscalzo J. Nitric oxide and cardiovascular system. J Cardiovasc Surg1994; 9: 361-371Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 1999; 43: 580-594Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 1999; 43: 580-594Han X, Shimoni Y, Giles WR. An obligatory role for nitric oxide in autonomic control of mammalian heart rate. J Physiol 1994; 476: 309-314Han X, Shimoni Y, Giles WR. An obligatory role for nitric oxide in autonomic control of mammalian heart rate. J Physiol 1994; 476: 309-314Minami N, Imai Y, Nishiyama H, Abe K. Role of nitric oxide in the development of vascular α1-adrenoreceptor desensitization and pressure diuresis in conscious rats. Hypertension 1997; 29: 969-975Minami N, Imai Y, Nishiyama H, Abe K. Role of nitric oxide in the development of vascular α1-adrenoreceptor desensitization and pressure diuresis in conscious rats. Hypertension 1997; 29: 969-975Tolins IP, Raij R. Role of endothelium-derived relaxing factor in hemodynamic response to acetylcholine in vivo. In: Nitric oxide from L-arginin: a bioregulatory system. Royal Society, London, 1989; 13Tolins IP, Raij R. Role of endothelium-derived relaxing factor in hemodynamic response to acetylcholine in vivo. In: Nitric oxide from L-arginin: a bioregulatory system. Royal Society, London, 1989; 13Thiemerman C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lypopolysaccharides in the rat in vivo. Eur J Pharmacol 1990; 182: 591-595Thiemerman C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lypopolysaccharides in the rat in vivo. Eur J Pharmacol 1990; 182: 591-595Gardiner SM, Compton AM, Bennett T et al. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15: 486-492Gardiner SM, Compton AM, Bennett T et al. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15: 486-492Zatz R, Baylis С. Chronic nitric oxide inhibition model six years on. Hypertension 1998; 32: 958-964Zatz R, Baylis С. Chronic nitric oxide inhibition model six years on. Hypertension 1998; 32: 958-964Gerova M. Nitric oxide compromised hypertension: facts and enigmas. Physiol Res 2000; 49: 27-35Gerova M. Nitric oxide compromised hypertension: facts and enigmas. Physiol Res 2000; 49: 27-35Baylis C, Mitruka В, Deng A. Chronic blockade of nitric oxide synthesis in the rat produced systemic hypertension and glomerular damage. J Clin Invest 1992; 90: 278-281Baylis C, Mitruka В, Deng A. Chronic blockade of nitric oxide synthesis in the rat produced systemic hypertension and glomerular damage. J Clin Invest 1992; 90: 278-281Chatziantoniou C, Boffa J, Ardaillou R, Dussaule J. Nitric oxide inhibition and early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. J Clin Invest 1998; 101: 2780-2789Chatziantoniou C, Boffa J, Ardaillou R, Dussaule J. Nitric oxide inhibition and early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. J Clin Invest 1998; 101: 2780-2789Sessa WC, Pritchard K, Seyedi N et al. Chronic exercise in dog increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circulat Res 1994; 74: 349-353Sessa WC, Pritchard K, Seyedi N et al. Chronic exercise in dog increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circulat Res 1994; 74: 349-353Koller A, Kaley G. Shear stress dependent regulation of vascular resistance in health and disease: role of endothelium. Endothelium 1996; 4: 247-272Koller A, Kaley G. Shear stress dependent regulation of vascular resistance in health and disease: role of endothelium. Endothelium 1996; 4: 247-272Celermajer DS, Sorensen KE, Gooch VM et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115Celermajer DS, Sorensen KE, Gooch VM et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115Panza JA, Casino PR, Kilcoyne СМ, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation1993; 87: 1468-1474Panza JA, Casino PR, Kilcoyne СМ, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation1993; 87: 1468-1474Antony I, Lerebours G, Nitemberg A. Loss of flow-dependent coronary artery dilatation in patients with hypertension. Circulation 1995; 91: 1624-1628Antony I, Lerebours G, Nitemberg A. Loss of flow-dependent coronary artery dilatation in patients with hypertension. Circulation 1995; 91: 1624-1628Lind L, Sarabi M, Millgard J. Methodological aspects of the evaluation of endothelium-dependent vasodilatation in the human forearm. Clin Physiol 1998; 18: 81-87Lind L, Sarabi M, Millgard J. Methodological aspects of the evaluation of endothelium-dependent vasodilatation in the human forearm. Clin Physiol 1998; 18: 81-87Egashira K, Suzuki S, Hirooka Y et al. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Hypertension 1995; 25: 201-206Egashira K, Suzuki S, Hirooka Y et al. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Hypertension 1995; 25: 201-206Panza JA, Quyyumi AA, Brush JEJr, Epstein SE. Abnormal endothelium-dependent relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27Panza JA, Quyyumi AA, Brush JEJr, Epstein SE. Abnormal endothelium-dependent relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27Anderson WD, Klein JL, Manoukian SV. Coronary flow mediated dilation is preserved in hypertensive patients. J Am Coc Cardiol 1994; 23: 107AAnderson WD, Klein JL, Manoukian SV. Coronary flow mediated dilation is preserved in hypertensive patients. J Am Coc Cardiol 1994; 23: 107AMinor RI, Myers PR, Guerra R Jr et al. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta.J Clin Invest 1990; 86: 2109-2116Minor RI, Myers PR, Guerra R Jr et al. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta.J Clin Invest 1990; 86: 2109-2116Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hyper-cholesterolemic patients by L-arginine. Lancet 1991; 338: 1546-1550Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hyper-cholesterolemic patients by L-arginine. Lancet 1991; 338: 1546-1550Cardillo C, Kilcoyne СМ, Quyyumi AA et al. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilatation in patients with essential hypertension. Circulation 1998; 97: 851-856Cardillo C, Kilcoyne СМ, Quyyumi AA et al. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilatation in patients with essential hypertension. Circulation 1998; 97: 851-856Rudic RD, Sessa WC. Nitric oxide in endothelial dysfunction and vascular remodeling: Clinical correlates and experimental links. Am J Hum Genet 1999; 64: 673-677Rudic RD, Sessa WC. Nitric oxide in endothelial dysfunction and vascular remodeling: Clinical correlates and experimental links. Am J Hum Genet 1999; 64: 673-677Birnbaum Y, Fishbein MC, Luo H et al. Regional remodeling of atherosclerotic arteries: a major determinant of clinical manifestations of disease. J Am Coll Cardiol 1997; 30: 1149-1164Birnbaum Y, Fishbein MC, Luo H et al. Regional remodeling of atherosclerotic arteries: a major determinant of clinical manifestations of disease. J Am Coll Cardiol 1997; 30: 1149-1164Nimaguchi K, Egashira K, Takemoto M et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995; 26: 957-962Nimaguchi K, Egashira K, Takemoto M et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995; 26: 957-962Luvara G, Pueyo M, Philippe M et al. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol 1998; 18: 1408-1416Luvara G, Pueyo M, Philippe M et al. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol 1998; 18: 1408-1416Godecke A, Decking UK, Ding Z et al. Coronary hemodynamics in endothelial NO synthase knockout mice. Circulat Res 1998; 82: 186-194Godecke A, Decking UK, Ding Z et al. Coronary hemodynamics in endothelial NO synthase knockout mice. Circulat Res 1998; 82: 186-194Huang PL, Huang Z, Mashimo H et al Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242Huang PL, Huang Z, Mashimo H et al Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242Moroi M, Zhang L, Yasuda T et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 1998; 101: 1225-1232Moroi M, Zhang L, Yasuda T et al. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest 1998; 101: 1225-1232Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131-3139Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131-3139Meeus F, Kourilsky O, Guerin AP et al. Pathophysiology of cardiovascular disease in hemodialysis patients. Kidney Int 2000; 58 [suppl 76]: 140-146Meeus F, Kourilsky O, Guerin AP et al. Pathophysiology of cardiovascular disease in hemodialysis patients. Kidney Int 2000; 58 [suppl 76]: 140-146Morris STW, McMurray JJV, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremical resistance arteries. Kidney Int2001; 60(3): 1077-1081Morris STW, McMurray JJV, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremical resistance arteries. Kidney Int2001; 60(3): 1077-1081Bennet-Richards KJ, Kattenhorn M, Donald AE et al. Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int 2002; 62(4): 1372-1377Bennet-Richards KJ, Kattenhorn M, Donald AE et al. Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int 2002; 62(4): 1372-1377Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodialysis Int 2004; 8(2): 118-123Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodialysis Int 2004; 8(2): 118-123Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney Int 2003; 63 [suppl] 84: 80-85Tyralla K, Amann K. Morphology of the heart and arteries in renal failure. Kidney Int 2003; 63 [suppl] 84: 80-85Kazuhiro S. Expression and regulation of endothelial nitric oxide synthase. TCM 1997; 7(1): 28-37Kazuhiro S. Expression and regulation of endothelial nitric oxide synthase. TCM 1997; 7(1): 28-37Robert MF, Rabelink TJ. Atherosclerosis and two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112Robert MF, Rabelink TJ. Atherosclerosis and two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-112Шебеко ВИ, Родионов ЮЯ. Дисфункция эндотелия при гиперхолестеринемии и атеросклерозе. Мед Новости 1997; (11): 12-17Шебеко ВИ, Родионов ЮЯ. Дисфункция эндотелия при гиперхолестеринемии и атеросклерозе. Мед Новости 1997; (11): 12-17Holvoet P. Endothelial dysfunction, oxidation of low-density lipoprotein and cardiovascular disease. Ther Apheresis and Dialysis 1999; 3(4): 287-292Holvoet P. Endothelial dysfunction, oxidation of low-density lipoprotein and cardiovascular disease. Ther Apheresis and Dialysis 1999; 3(4): 287-292Galle J, Schneider R, Heinloth A et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int 1999; 55(4): 1450-1456Galle J, Schneider R, Heinloth A et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int 1999; 55(4): 1450-1456Heermeir K, Schneider R, Heinloth A et al. Oxidative stress mediates apoptosis induced by oxidized low-density lipoprotein and oxidized lipoprotein(a). Kidney Int 1999; 56(4): 1310-1315Heermeir K, Schneider R, Heinloth A et al. Oxidative stress mediates apoptosis induced by oxidized low-density lipoprotein and oxidized lipoprotein(a). Kidney Int 1999; 56(4): 1310-1315Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-1051Ludmer PL, Selwyn AP, Shook TL et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-1051Britten MB, Zeiher AM, Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245(4): 315-321Britten MB, Zeiher AM, Schachinger V. Clinical importance of coronary endothelial vasodilator dysfunction and therapeutic options. J Intern Med 1999; 245(4): 315-321Noon JP, Walker BR, Hand MF, Webb HD. Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. Br J Clin Pharmacol 1998; 45 (6): 545–551Noon JP, Walker BR, Hand MF, Webb HD. Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. Br J Clin Pharmacol 1998; 45 (6): 545–551Creager MA, Cooke JP, Mendelsohn MP et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86: 228-234Creager MA, Cooke JP, Mendelsohn MP et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86: 228-234Lu Q, Eriksson M, Jogestrand T et al. Micro- and macrocirculatory effects of apheresis in patients with familial hyperlipidemia. Ther Apheresis and Dialysis 2003; 7(1): 115-120Lu Q, Eriksson M, Jogestrand T et al. Micro- and macrocirculatory effects of apheresis in patients with familial hyperlipidemia. Ther Apheresis and Dialysis 2003; 7(1): 115-120Freiman PC, Mitchell GG, Heistad DD et al. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res 1986; 58: 783-789Freiman PC, Mitchell GG, Heistad DD et al. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res 1986; 58: 783-789Harrison DG, Armstrong ML, Freiman PC et al. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987; 80: 1808-1811Harrison DG, Armstrong ML, Freiman PC et al. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987; 80: 1808-1811Marchesi S, Lupattelli G, Siepi D et al. Oral L-arginine administration attenuates postprandial endothelial dysfunction in young healthy males. J Clin Pharm Ther 2001; 25(5): 343-349Marchesi S, Lupattelli G, Siepi D et al. Oral L-arginine administration attenuates postprandial endothelial dysfunction in young healthy males. J Clin Pharm Ther 2001; 25(5): 343-349Algotsson A. Serum lipids and lipoproteins are correlated to skin vessel reactivity in healthy women. J Interrn Med 1996; 239(2): 147-153Algotsson A. Serum lipids and lipoproteins are correlated to skin vessel reactivity in healthy women. J Interrn Med 1996; 239(2): 147-153Harrison DG, Armstrong ML, Freiman PC et al. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987; 80: 1808-1811Harrison DG, Armstrong ML, Freiman PC et al. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987; 80: 1808-1811Benzuly KH, Padgett RC, Kaul S et al. Functional improvement precedes structural regression of atherosclerosis. Circulation 1994; 89: 1810-1818Benzuly KH, Padgett RC, Kaul S et al. Functional improvement precedes structural regression of atherosclerosis. Circulation 1994; 89: 1810-1818Srisawat S, Phivthong-Ingam L, Unchern S et al. Improvement of vascular function by chronic administration of a cyclo-oxygenase inhibitor in cholesterol-fed rabbits. Clin Exp Pharm Physiol 2003; 30 (5-6): 405-409Srisawat S, Phivthong-Ingam L, Unchern S et al. Improvement of vascular function by chronic administration of a cyclo-oxygenase inhibitor in cholesterol-fed rabbits. Clin Exp Pharm Physiol 2003; 30 (5-6): 405-409Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol 1996; 271: 1424-1437Beckman JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol 1996; 271: 1424-1437Sand C, Peters SLM, Pfaffendorf M et al. Effects of hypochlorite and hydrogen peroxide on cardiac autonomic receptors and vascular endothelial function. Clin Exp Pharm Physiol 2003; 30 (4): 249-255Sand C, Peters SLM, Pfaffendorf M et al. Effects of hypochlorite and hydrogen peroxide on cardiac autonomic receptors and vascular endothelial function. Clin Exp Pharm Physiol 2003; 30 (4): 249-255Martinet W, De Meyer GRY, Herman AG, Kockx M. Reactive oxygen species induce RNA damage in human atherosclerosis. Eur J Clin Invest 2004; 34(5): 323-329Martinet W, De Meyer GRY, Herman AG, Kockx M. Reactive oxygen species induce RNA damage in human atherosclerosis. Eur J Clin Invest 2004; 34(5): 323-329Баранова ЕИ, Большакова ОО. Клиническое значение гипергомоцистеинемии. Артериальная гипертензия 2004; 10(1): 12-15Баранова ЕИ, Большакова ОО. Клиническое значение гипергомоцистеинемии. Артериальная гипертензия 2004; 10(1): 12-15Malinow MR. Hyperhomocysteinemia: a common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990; 81: 2004-2006Malinow MR. Hyperhomocysteinemia: a common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990; 81: 2004-2006Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877-881Selhub J, Jacques PF, Boston AG et al. Association between plasma homocysteine concentrations and extracranial catotid-artery stenosis. N Engl J Med 1995; 332: 286-291Selhub J, Jacques PF, Boston AG et al. Association between plasma homocysteine concentrations and extracranial catotid-artery stenosis. N Engl J Med 1995; 332: 286-291Stampfer M, Malinow M. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995; 332: 328-329Stampfer M, Malinow M. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 1995; 332: 328-329Graham M, Daly L, Refsum H et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA 1997; 277(22): 1775-1781Graham M, Daly L, Refsum H et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA 1997; 277(22): 1775-1781Tawacol A, Omland T, Gerhard M et al. Hyperhomocyst(e)inemia is associated with impaired endothelium dependent vasodilation in humans. Circulation 1997; 95: 1119-1121Tawacol A, Omland T, Gerhard M et al. Hyperhomocyst(e)inemia is associated with impaired endothelium dependent vasodilation in humans. Circulation 1997; 95: 1119-1121Welch G, Loscalzo J. Homocysteine and atherosclerosis. New Engl J Med 1998; 338(15): 1042-1050Welch G, Loscalzo J. Homocysteine and atherosclerosis. New Engl J Med 1998; 338(15): 1042-1050Wang XL, Duarte N, Cai H et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis 1999; 146: 133-140Wang XL, Duarte N, Cai H et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis 1999; 146: 133-140Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741Harker LA, Ross R, Slichter SJ, Scott CR. Homocysteine-induced arteriosclerosis: the role of endothelial injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741Stamler JS, Osborne JA, Jaraki O et al. Adverse vascular effects of homocysteine are modulated by endothelial derived relaxing factor and related oxide of nitrogen. J Clin Invest 1993; 91: 308-318Stamler JS, Osborne JA, Jaraki O et al. Adverse vascular effects of homocysteine are modulated by endothelial derived relaxing factor and related oxide of nitrogen. J Clin Invest 1993; 91: 308-318Van den Berg M, Boers GH, Franken DG et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176-181Van den Berg M, Boers GH, Franken DG et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176-181Lentz SR, Sobey CG, Piegors DJ et al. Vascular dysfunction in monkeys with diet induced hyperhomocysteinemia. J Clin Invest 1996; 98: 24-29Lentz SR, Sobey CG, Piegors DJ et al. Vascular dysfunction in monkeys with diet induced hyperhomocysteinemia. J Clin Invest 1996; 98: 24-29Woo KS, Chook P, Lolin YI et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-2544Woo KS, Chook P, Lolin YI et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-2544Lambert J, van den Berg M, Steyn M et al. Familial hyperhomocysteinaemia and endothelium-dependent vasodilation and arterial distensibility of large arteries. Cardiovasc Res 1999; 42: 743-751Lambert J, van den Berg M, Steyn M et al. Familial hyperhomocysteinaemia and endothelium-dependent vasodilation and arterial distensibility of large arteries. Cardiovasc Res 1999; 42: 743-751Шевченко ОП, Олефриенко ГА. Гипергомоцистеинемия и ее клиническое значение. Лаборатория 2002; (1): 3-7Шевченко ОП, Олефриенко ГА. Гипергомоцистеинемия и ее клиническое значение. Лаборатория 2002; (1): 3-7Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994; 236: 603-617Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994; 236: 603-617Berwanger CL, Jeremy JY, Stansby GD. Homocysteine and vascular disease. Br J Surg 1995; 82: 726-731Berwanger CL, Jeremy JY, Stansby GD. Homocysteine and vascular disease. Br J Surg 1995; 82: 726-731Celermajer DS, Sorenson KE, Ryalls M et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocysteinuria but not in their heterozygous parents. J Am Coll Cardiol 1993; 22: 854-858Celermajer DS, Sorenson KE, Ryalls M et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocysteinuria but not in their heterozygous parents. J Am Coll Cardiol 1993; 22: 854-858Upchurch GR, Welch G, Fabian A et al. Stimulation of endothelial nitric oxide production by homocysteine. Atherosclerosis 1997; 132: 177-185Upchurch GR, Welch G, Fabian A et al. Stimulation of endothelial nitric oxide production by homocysteine. Atherosclerosis 1997; 132: 177-185Demuth K, Atger V, Borderie D et al. Homocysteine decreases endothelin-1 production by cultured human endothelial cells. Eur J Biochem 1999; 263(2): 367-372Demuth K, Atger V, Borderie D et al. Homocysteine decreases endothelin-1 production by cultured human endothelial cells. Eur J Biochem 1999; 263(2): 367-372Emsley AM, Jeremy JY, Gomes GN et al. Investigation of the inhibitory effects of homocysteine and copper on nitric oxide-mediated relaxation of rat isolated aorta. Br J Pharmacol 1999; 126: 1034-1040Emsley AM, Jeremy JY, Gomes GN et al. Investigation of the inhibitory effects of homocysteine and copper on nitric oxide-mediated relaxation of rat isolated aorta. Br J Pharmacol 1999; 126: 1034-1040Zhang X, Li H, Jin H et al. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 2000; 279: 671-678Zhang X, Li H, Jin H et al. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 2000; 279: 671-678Weiss N, Heydrick SJ, Postea O et al. Influence of hyperhomocysteinemia on the cellular redox state – impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med 2003; 41: 1455-1461Weiss N, Heydrick SJ, Postea O et al. Influence of hyperhomocysteinemia on the cellular redox state – impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med 2003; 41: 1455-1461Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996; 98(1): 5-7Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996; 98(1): 5-7Jia L, Furchgott RF. Inhibition by sulph-hydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor. J Pharmacol Exp Ther 1993; 267: 371-378Jia L, Furchgott RF. Inhibition by sulph-hydryl compounds of vascular relaxation induced by nitric oxide and endothelium-derived relaxing factor. J Pharmacol Exp Ther 1993; 267: 371-378Emsley A, Plane F, Angelini GD, Jeremy JY. Copper interacts with homocysteine to inhibit nitric oxide formation in the rat isolated aorta. Br J Pharmacol 1997; 122: 47-53Emsley A, Plane F, Angelini GD, Jeremy JY. Copper interacts with homocysteine to inhibit nitric oxide formation in the rat isolated aorta. Br J Pharmacol 1997; 122: 47-53Glyglewski RJ, Palmer RMJ, Moncada S. Superoxide anion plays a role in the breakdown of endothelium-derived relaxing factor. Nature 1986; 320: 454-456Glyglewski RJ, Palmer RMJ, Moncada S. Superoxide anion plays a role in the breakdown of endothelium-derived relaxing factor. Nature 1986; 320: 454-456Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factors. Am J Physiol 1986; 250: H822-H827Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factors. Am J Physiol 1986; 250: H822-H827McAninly J, Williams DLH, Askew SC et al. Metal-ion catalysis in nitrosothiol (RSNO) decomposition. J Chem Soc Commun 1993; 23: 1758-1759McAninly J, Williams DLH, Askew SC et al. Metal-ion catalysis in nitrosothiol (RSNO) decomposition. J Chem Soc Commun 1993; 23: 1758-1759Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-1376Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-1376Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low-density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 10098-10103Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfur-containing amino acids in superoxide production and modification of low-density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 10098-10103Upchurch GR, Welch GN, Loscalzo J. Homocysteine, EDRF and endothelial function. J Nutr 1996; 126: 1290S-1294SUpchurch GR, Welch GN, Loscalzo J. Homocysteine, EDRF and endothelial function. J Nutr 1996; 126: 1290S-1294SWelch G, Upchurch G, Loscalzo J. Hyperhomocysteinemia and atherothrombosis. Ann NY Acad Sci 1997; 811: 48-58Welch G, Upchurch G, Loscalzo J. Hyperhomocysteinemia and atherothrombosis. Ann NY Acad Sci 1997; 811: 48-58Coppola A, Davi G, De Stefano V et al. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000; 26: 243-254Coppola A, Davi G, De Stefano V et al. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000; 26: 243-254Fu W, Dudman N, Perry M, Wang H. Homocysteinemia attenuates hemodynamic responses to nitric oxide in vivo. Atherosclerosis 2002; 161(1): 169-176Fu W, Dudman N, Perry M, Wang H. Homocysteinemia attenuates hemodynamic responses to nitric oxide in vivo. Atherosclerosis 2002; 161(1): 169-176Perna AF, Ingrosso D, Lombardi C et al. Possible mechanisms of homocysteine toxicity. Kidney Int 2003; 63 [suppl 84]: S137-S140Perna AF, Ingrosso D, Lombardi C et al. Possible mechanisms of homocysteine toxicity. Kidney Int 2003; 63 [suppl 84]: S137-S140Hucks D, Thuraisingam RC, Raftery MJ, Yaqoob MM. Homocysteine induced impairment of nitric oxide-dependent vasorelaxation is reversible by the superoxide dismutase mimetic TEMPOL. Nephrol Dial Transplant 2004; 19(8): 1999-2005Hucks D, Thuraisingam RC, Raftery MJ, Yaqoob MM. Homocysteine induced impairment of nitric oxide-dependent vasorelaxation is reversible by the superoxide dismutase mimetic TEMPOL. Nephrol Dial Transplant 2004; 19(8): 1999-2005Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular in end stage renal disease (SPACE): randomized placebo controlled trial. Lancet 2000; 356: 1213-1218Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular in end stage renal disease (SPACE): randomized placebo controlled trial. Lancet 2000; 356: 1213-1218Tepel M, van der Giet M, Statz M et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end stage renal failure. Circulation 2003; 107: 992-994Tepel M, van der Giet M, Statz M et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end stage renal failure. Circulation 2003; 107: 992-994Drunat S, Moati N, Paul JL. Homocysteine-induced decrease in endothelin-1 production is initiated at extracellular level and involves oxidative products. Eur J Biochem 2001; 268 (20): 5287-5291Drunat S, Moati N, Paul JL. Homocysteine-induced decrease in endothelin-1 production is initiated at extracellular level and involves oxidative products. Eur J Biochem 2001; 268 (20): 5287-5291Pathasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by acetyl LDL receptor. Biochem Biophys Acta 1987; 917: 337-340Pathasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by acetyl LDL receptor. Biochem Biophys Acta 1987; 917: 337-340Chin JH, Azhar S, Hoffman BB. Inactivation of endothelium-derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89: 10-18Chin JH, Azhar S, Hoffman BB. Inactivation of endothelium-derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89: 10-18Blom HJ. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinemia. Eur J Clin Invest 1995; 25: 149-154Blom HJ. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinemia. Eur J Clin Invest 1995; 25: 149-154Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 27: 319-324Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 27: 319-324Tawacol A, Forgione M, Stueblinger M et al. Homocysteine impairs coronary microvascular dilator function in humans. JACC 2002; 40(6): 1051-1058Tawacol A, Forgione M, Stueblinger M et al. Homocysteine impairs coronary microvascular dilator function in humans. JACC 2002; 40(6): 1051-1058Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345(22): 1593-1600Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345(22): 1593-1600Van Dijk RA, Rauwerda JA, Steyn M et al. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol2001; 21: 2072-2079Van Dijk RA, Rauwerda JA, Steyn M et al. Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol2001; 21: 2072-2079Toole JF, Malinow MR, Chambless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-575Toole JF, Malinow MR, Chambless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-575Wrone EM, Hornberger JM, Zehnder J et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15: 420-426Wrone EM, Hornberger JM, Zehnder J et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15: 420-426Van Guldener C, Janssen MJ, Lambert J et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 106-112Van Guldener C, Janssen MJ, Lambert J et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 106-112Austen SK, Coombes JS, Fassett RG. Homocysteine-lowering therapy in renal disease. Clin Nephrol 2003; 60: 375-385Austen SK, Coombes JS, Fassett RG. Homocysteine-lowering therapy in renal disease. Clin Nephrol 2003; 60: 375-385Vallance P, Leone A, Calver A et al. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 [suppl 12]: S60-S62Vallance P, Leone A, Calver A et al. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 [suppl 12]: S60-S62Fickling SA, Leone AM, Nussey SS et al. Synthesis of NG, Ng dimethylarginine by human endothelial cells. Endothelium 1993; 1: 137–140Fickling SA, Leone AM, Nussey SS et al. Synthesis of NG, Ng dimethylarginine by human endothelial cells. Endothelium 1993; 1: 137–140Boger RH, Bode-Boger SM, Tsao PS et al. The endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) exerts pro-atherosclerotic effects in cultural human endothelial cells. Circulation 1997; 96; [suppl 1]: 1588Boger RH, Bode-Boger SM, Tsao PS et al. The endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) exerts pro-atherosclerotic effects in cultural human endothelial cells. Circulation 1997; 96; [suppl 1]: 1588Bode-Boger SM, Boger RH, Kieke S et al. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598-603Bode-Boger SM, Boger RH, Kieke S et al. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598-603Boger RH, Bode-Boger SM, Phivthong-Ingam L et al. Dietary L-arginine slows the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997; 96: 1282-1290Boger RH, Bode-Boger SM, Phivthong-Ingam L et al. Dietary L-arginine slows the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997; 96: 1282-1290Boger RH, Bode-Boger SM, Thiele W et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive. Circulation 1997; 95: 2068-2074Boger RH, Bode-Boger SM, Thiele W et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive. Circulation 1997; 95: 2068-2074Boger RH, Bode-Boger SM, Szuba A et al. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847Boger RH, Bode-Boger SM, Szuba A et al. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994; 236: 603-617Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med 1994; 236: 603-617Boger RH, Bode-Boger SM, Sydow K et al. Plasma concentration of asymmetric dymethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000: 20; 1557-1561Boger RH, Bode-Boger SM, Sydow K et al. Plasma concentration of asymmetric dymethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000: 20; 1557-1561Hornig B, Bode-Boger SM, Arakawa N et al. Lack of improvement of homocyst(e)ine-induced endothelial dysfunction during supplementation with B vitamins in patients with arterial occlusive disease. Circulation 1999; 100 [suppl 1]: 757Hornig B, Bode-Boger SM, Arakawa N et al. Lack of improvement of homocyst(e)ine-induced endothelial dysfunction during supplementation with B vitamins in patients with arterial occlusive disease. Circulation 1999; 100 [suppl 1]: 757Zoccali C, Mallamaci LS, Maas R et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62(1): 339-345Zoccali C, Mallamaci LS, Maas R et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62(1): 339-345Fliser D, Kielstein JT, Haller H, Bode-Boger SM. Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Kidney Int 2003; 63 [suppl 84]: 37-43Fliser D, Kielstein JT, Haller H, Bode-Boger SM. Asymmetric dimethylarginine: A cardiovascular risk factor in renal disease? Kidney Int 2003; 63 [suppl 84]: 37-43Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003; 63 [suppl 85]: 105-111Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003; 63 [suppl 85]: 105-111Suliman ME, Stenvinkel P, Heimburger O et al. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis 2002; 40: 480-488Suliman ME, Stenvinkel P, Heimburger O et al. Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis 2002; 40: 480-488Faraci FM, Orgren K, Heistad DD. Impaired relaxation of the carotid artery during activation of ATP-sensitive potassium channels in atherosclerotic monkeys. Stroke 1994; 25: 178-182Faraci FM, Orgren K, Heistad DD. Impaired relaxation of the carotid artery during activation of ATP-sensitive potassium channels in atherosclerotic monkeys. Stroke 1994; 25: 178-182Tsai JC, Perrella MA, Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-6373Tsai JC, Perrella MA, Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-6373Tang L, Mamotte CD, van Bockxmeer FM, Taylor RR. The effect homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis 1998; 136: 169-173Tang L, Mamotte CD, van Bockxmeer FM, Taylor RR. The effect homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis 1998; 136: 169-173Hansrani M, Gillespie J, Stransby G. Homocyseine in myointimal hyperplasia. Eur J Vasc Endovasc Surg 2002; 23: 3-10Hansrani M, Gillespie J, Stransby G. Homocyseine in myointimal hyperplasia. Eur J Vasc Endovasc Surg 2002; 23: 3-10Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074-2081Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074-2081Noris M, Remuzzi G. Physiology and pathophysiology of nitric oxide in chronic renal disease. Proc Assoc Am Phys 1999; 111(6): 602-608Noris M, Remuzzi G. Physiology and pathophysiology of nitric oxide in chronic renal disease. Proc Assoc Am Phys 1999; 111(6): 602-608Benchetrit S, Green J, Katz D et al. Early endothelial dysfunction following renal mass reduction in rats. Eur J Clin Invest 2003; 33(1): 26-31Benchetrit S, Green J, Katz D et al. Early endothelial dysfunction following renal mass reduction in rats. Eur J Clin Invest 2003; 33(1): 26-31Asahi K, Ichimori K, Nakazawa H et al. Nitric oxide inhibits the formation of advanced end products. Kidney Int 2000; 58(4): 1780-1785Asahi K, Ichimori K, Nakazawa H et al. Nitric oxide inhibits the formation of advanced end products. Kidney Int 2000; 58(4): 1780-1785Stenvinkel P, Alvestrand A. Review Articles Inflammation in end-stage renal disease: sources, consequences and therapy. Semin Dialysis 2002; 15(5): 329-335Stenvinkel P, Alvestrand A. Review Articles Inflammation in end-stage renal disease: sources, consequences and therapy. Semin Dialysis 2002; 15(5): 329-335Ребров АП, Зелепукина НЮ. Дисфункция эндотелия у больных хроническим гломерулонефритом в различных стадиях почечной недостаточности. Нефрология и диализ 2001; 3(4): 39-46Ребров АП, Зелепукина НЮ. Дисфункция эндотелия у больных хроническим гломерулонефритом в различных стадиях почечной недостаточности. Нефрология и диализ 2001; 3(4): 39-46Watts GF, Herrmann S, Dogra GK et al. Vascular function of the peripheral circulation in patients with nephrosis. Kidney Int 2001; 60(1): 182-187Watts GF, Herrmann S, Dogra GK et al. Vascular function of the peripheral circulation in patients with nephrosis. Kidney Int 2001; 60(1): 182-187Dogra GK, Watts GF, Herrmann S et al. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int 2002; 62 (2): 550-556Dogra GK, Watts GF, Herrmann S et al. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int 2002; 62 (2): 550-556Hausberg M, Kisters K, Kosch M et al. Flow-mediated vasodilation and distensibility of the brachial artery in renal allograft recipients. Kidney Int 1999; 55(3):1104-1109Hausberg M, Kisters K, Kosch M et al. Flow-mediated vasodilation and distensibility of the brachial artery in renal allograft recipients. Kidney Int 1999; 55(3):1104-1109Asberg A, Holdaas H, Jardine AG et al. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clin Transplantation 2003; 17(4): 385-391Asberg A, Holdaas H, Jardine AG et al. Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation. Clin Transplantation 2003; 17(4): 385-391Paisley KE, Beaman M, Tooke JE et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int 2003; 63(2): 624-631Paisley KE, Beaman M, Tooke JE et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int 2003; 63(2): 624-631Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int 1998; 53(4): 1068-1073Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int 1998; 53(4): 1068-1073London GM, Pannier B, Agharazii M et al. Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int2004; 65(2): 700-705London GM, Pannier B, Agharazii M et al. Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int2004; 65(2): 700-705Pannier B, Guerin AP, Marchais SJ et al. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end stage renal disease. Kidney Int 2000; 57(3): 1091-1097Pannier B, Guerin AP, Marchais SJ et al. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end stage renal disease. Kidney Int 2000; 57(3): 1091-1097Wang D, Iversen J, Wilcox CS, Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64(4): 1381-1386Wang D, Iversen J, Wilcox CS, Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64(4): 1381-1386Al-Nimri MA, Komers R, Oyama TT et al. Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int 2003; 63(5):1776-1782Al-Nimri MA, Komers R, Oyama TT et al. Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int 2003; 63(5):1776-1782Oflaz H, Turkmen A, Kazancioglu R et al. The effect of calcineurin inhibitors on endothelial function in renal transplant recipients. Clin Tranplantation 2003; 17(3): 212-217Oflaz H, Turkmen A, Kazancioglu R et al. The effect of calcineurin inhibitors on endothelial function in renal transplant recipients. Clin Tranplantation 2003; 17(3): 212-217Annuk M, Zilmer M, Fellstrom B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: Impact on cardiovascular disease. Kidney Int 2003; 63 [suppl 84]: 50-54Annuk M, Zilmer M, Fellstrom B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: Impact on cardiovascular disease. Kidney Int 2003; 63 [suppl 84]: 50-54

The authors declare that there are no conflicts of interest present.